- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Pre-term birth.
Displaying page 1 of 1.
EudraCT Number: 2004-002312-29 | Sponsor Protocol Number: INOT -27 | Start Date*: 2005-01-10 | |||||||||||
Sponsor Name:INO Therapeutics | |||||||||||||
Full Title: The Effects of Nitric Oxide for Inhalation on the development of chronic lung disease in pre-term infants. | |||||||||||||
Medical condition: Prevention of chronic lung disease in pre-term infants ( gestational age < 29 weeks) with respiratory distress. | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) GB (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007550-66 | Sponsor Protocol Number: Emulipid | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: Lipidic emulsions influence on immune response of pre-term VLBW newborns treated with total parenteral nutrition | |||||||||||||
Medical condition: very low birth weight newborn | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002800-16 | Sponsor Protocol Number: C3591024 | Start Date*: 2019-12-10 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANT... | |||||||||||||
Medical condition: Infections with suspected or confirmed Gram-negative pathogens | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) EE (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001707-38 | Sponsor Protocol Number: PN-0709 | Start Date*: 2007-07-31 | ||||||||||||||||
Sponsor Name:University Hospital | ||||||||||||||||||
Full Title: A phase IIIb, open, controlled study to evaluate the immunogenicity, and safety of 7PCV Prevenar vaccine in pre-term infants | ||||||||||||||||||
Medical condition: Premature children suffer from large variety of different accompanying diseases. Pneumoccocal diseases creates substantial proportion especially in children with undergoing diseases of respiratory ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002405-26 | Sponsor Protocol Number: MK-1654-004 | Start Date*: 2021-01-14 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | ||||||||||||||||||
Full Title: A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | ||||||||||||||||||
Medical condition: Prevention of RSV | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA FI (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005996-11 | Sponsor Protocol Number: MK-1654-007 | Start Date*: 2021-08-26 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for S... | |||||||||||||
Medical condition: Prevention of Respiratory syncytial virus (RSV) infection in infants and children at increased risk for severe RSV disease | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) Outside EU/EEA HU (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002624-28 | Sponsor Protocol Number: FIT-EU-04 | Start Date*: 2015-09-24 |
Sponsor Name:Nutrinia Ltd. | ||
Full Title: A Multi-center, Double-blind, Randomized Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Gastrointestinal Maturation in Preterm Infants. | ||
Medical condition: Gastrointestinal Maturation in Preterm Infants. | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-005336-23 | Sponsor Protocol Number: Baby-OSCAR | Start Date*: 2014-12-16 |
Sponsor Name:University of Oxford | ||
Full Title: Outcome After Selective Early Treatment for Closure of Patent Ductus Arteriosus in Pre-term Babies | ||
Medical condition: Patent ductus arteriosus of the newborn | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000456-15 | Sponsor Protocol Number: 3518 | Start Date*: 2015-05-19 | |||||||||||
Sponsor Name:Kings College London [...] | |||||||||||||
Full Title: The prevention of pre-term birth in women who develop a short cervix. A multi-centre randomised controlled trial to compare three treatments; cervical cerclage, cervical pessary and vaginal proges... | |||||||||||||
Medical condition: Short Cervix in Pregnancy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000048-17 | Sponsor Protocol Number: NN1250-4300 | Start Date*: 2017-10-12 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes. | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IE (Completed) GR (Completed) ES (Prematurely Ended) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001714-96 | Sponsor Protocol Number: R2222-RSV-1332 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in ... | |||||||||||||
Medical condition: Medically attended respiratory syncytial virus infection | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) HU (Completed) FI (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003889-14 | Sponsor Protocol Number: C12-75 | Start Date*: 2014-12-09 | ||||||||||||||||
Sponsor Name:Institut National de la Santé et de la Research Médicale | ||||||||||||||||||
Full Title: A randomised, placebo controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants | ||||||||||||||||||
Medical condition: Bronchopulmonary Dysplasia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) DE (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004890-29 | Sponsor Protocol Number: FIT-PIV | Start Date*: 2023-03-09 | |||||||||||
Sponsor Name:Elgan Pharma Ltd | |||||||||||||
Full Title: A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants | |||||||||||||
Medical condition: Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants. | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005281-30 | Sponsor Protocol Number: DUR001-306 | Start Date*: 2016-11-03 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Allergan Ltd. | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed. | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Completed) PL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002606-20 | Sponsor Protocol Number: CV185-325/B0661037 | Start Date*: 2015-11-06 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT | |||||||||||||
Medical condition: Venous Thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) Outside EU/EEA AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) PT (Completed) IT (Not Authorised) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000199-14 | Sponsor Protocol Number: N01009 | Start Date*: 2004-11-25 | |||||||||||
Sponsor Name:UCB Pharma S.A. [...] | |||||||||||||
Full Title: A double-blind, randomized, multicenter, placebo-controlled, in-patients maximum 34 day study of levetiracetam oral solution (20-50 mg/kg/day) as adjunctive treatment of refractory partial onset se... | |||||||||||||
Medical condition: Epilepsy - Refractory Partial Onset Seizures | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) BE (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004318-16 | Sponsor Protocol Number: DAS181-3-01 | Start Date*: 2020-01-16 | |||||||||||
Sponsor Name:Ansun Biopharma, Inc. | |||||||||||||
Full Title: A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects | |||||||||||||
Medical condition: Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-004195-42 | Sponsor Protocol Number: FIT-05 | Start Date*: 2023-04-13 | |||||||||||
Sponsor Name:Elgan Pharma Ltd | |||||||||||||
Full Title: A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Basket Study to Assess the Safety of ELGN-2112 in Populations of Interest | |||||||||||||
Medical condition: Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants. | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) SE (Ongoing) ES (Ongoing) NL (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
